Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Morita

Showing results (11-20 of 757) with videos related to

Pageof 76
Sort By:
Journal of Biopharmaceutical Statistics|August 16, 2023
Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trialsYuichiro Kaneko, Satoshi Morita
Statistics in Medicine|September 6, 2023
Frequentist analysis of basket trials with one-sample Mantel-Haenszel proceduresSatoshi Hattori, Satoshi Morita
Journal of Biopharmaceutical Statistics|June 2, 2026
Determining the cutpoint of a continuous predictive biomarker via Bayesian sensitive subpopulation findingWeiran Ye, Satoshi Morita
Statistics in Medicine|May 29, 2026
Exploring Sensitive Biomarkers Associated With Short-Term Responses and Long-Term Outcomes Using Bayesian Additive Regression TreesZixuan Yao, Satoshi Morita
Clinical Trials (London, England)|March 17, 2006
Estimation of the average causal effect among subgroups defined by post-treatment variablesYutaka Matsuyama, Satoshi Morita
Therapeutic Innovation & Regulatory Science|September 20, 2018
A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding StudiesTomoyuki Kakizume, Satoshi Morita
Journal of Biopharmaceutical Statistics|February 9, 2018
Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trialFumihiro Takahashi, Satoshi Morita
Biometrics|March 4, 2017
Bayesian population finding with biomarkers in a randomized clinical trialSatoshi Morita, Peter Müller
Therapeutic Innovation & Regulatory Science|January 3, 2023
Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent TailsKentaro Ueno, Satoshi Morita
Pharmaceutical Statistics|November 4, 2006
Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study designSatoshi Morita, Junichi Sakamoto
Pageof 76

Showing results (11-20 of 757) with videos related to

Sort By:
Pageof 76
Journal of Biopharmaceutical Statistics|August 16, 2023
Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trialsYuichiro Kaneko, Satoshi Morita
Statistics in Medicine|September 6, 2023
Frequentist analysis of basket trials with one-sample Mantel-Haenszel proceduresSatoshi Hattori, Satoshi Morita
Journal of Biopharmaceutical Statistics|June 2, 2026
Determining the cutpoint of a continuous predictive biomarker via Bayesian sensitive subpopulation findingWeiran Ye, Satoshi Morita
Statistics in Medicine|May 29, 2026
Exploring Sensitive Biomarkers Associated With Short-Term Responses and Long-Term Outcomes Using Bayesian Additive Regression TreesZixuan Yao, Satoshi Morita
Clinical Trials (London, England)|March 17, 2006
Estimation of the average causal effect among subgroups defined by post-treatment variablesYutaka Matsuyama, Satoshi Morita
Therapeutic Innovation & Regulatory Science|September 20, 2018
A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding StudiesTomoyuki Kakizume, Satoshi Morita
Journal of Biopharmaceutical Statistics|February 9, 2018
Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trialFumihiro Takahashi, Satoshi Morita
Biometrics|March 4, 2017
Bayesian population finding with biomarkers in a randomized clinical trialSatoshi Morita, Peter Müller
Therapeutic Innovation & Regulatory Science|January 3, 2023
Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent TailsKentaro Ueno, Satoshi Morita
Pharmaceutical Statistics|November 4, 2006
Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study designSatoshi Morita, Junichi Sakamoto
Pageof 76